The Department of Medicine I (Med. Klinik und Poliklinik I) includes the disciplines hematology/oncology, gastroenterology, pneumology and intensive care. The main focuses of research are hematologic malignancies, solid tumors and immunotherapy.
Dresden is the coordinating center of a nationwide clinical study group (Study Alliance Leukemia). Within the mentioned consortium, novel pharmacological and cellular therapies are developed within phase I to III clinical trials. This is achieved either within independent investigator-initiated or industry sponsored clinical trials. Novel combination therapies are studied in multi-institutional trials and a dedicated early clinical trial unit. A major strength within the department is the area of hematopoietic stem cell transplantation and adoptive immunotherapy. In addition, Dresden PIs have been successful in establishing novel molecular biomarkers for therapy guidance and have recently embarked on collaborations in the area of functional drug screening.
The area of oncology is dedicated to GI cancer with a specific focus on colorectal and pancreatic cancer. Dresden PIs are representatives of internationally active study groups in both of these disease entities. Key discoveries include the introduction of novel chemo-immunotherapeutic approaches.
Within the department novel immunotherapeutic strategies employing bispecific antibodies and genetically modified T cells are developed for first-in-man applications together with the department of immunology, department of radiopharmaceutics and local start-up companies.
